



Strategies in mechanical interventions for 
acute MI: facilitated and rescue PCI
whether Primary Percutaneous Coronary Intervention (PCI) or 
administration of thrombolytic drugs is the better initial strategy. A 
review of 23 randomized trials enrolling 7 739 patients has established 
the superiority of Primary PCI in minimizing death, reinfarction, and 
stroke.(4) Primary PCI results in better arterial patency rates(5) and 
avoids the life-threatening complication of intracranial haemorrhage 
associated with thrombolytic drugs.(1)
There are major logistical limitations that limit the applicability of 
primary PCI in the South African context. Facilities that are equipped 
for primary PCI are limited in number, and distances from community 
hospitals are often great. Best results are achieved when a primary PCI 
facility is available 24 hours a day, 365 days a year,(6) and this is not 
achievable in South Africa due to limited resources. As a result, most 
South Africans with STEMI, who present to hospital within the 
therapeutic window of opportunity will receive a thrombolytic agent 
rather than primary PCI. The question as to whether lytic therapy can 
be improved by adjunctive immediate PCI and the management of 
failed thrombolytic therapy are important issues in South Africa.
There are 3 different time-related PCI strategies that can be applied 
after initiation of fi brinolysis: facilitated PCI involves the administration 
of fi brinolytic therapy with a view to improving fl ow in the infarct-
related artery before planned immediate PCI.  Rescue PCI is PCI 
performed when there is failure of fi brinolysis, usually indicated by 
ongoing chest pain and/or the absence of ST-segment resolution at 60 
to 90 minutes after initiation of fi brinolytic therapy. The third strategy is 
that of systematic early PCI,  24 hours after administration of fi brinolysis 
irrespective of the latter’s success, rather than delayed and/or ischemia-
driven PCI.
FACILITATED PCI                                                              
Facilitated PCI is a strategy in which a patient with evolving, acute ST-
elevation myocardial infarction is given a pharmacological agent, 
followed by immediate PCI, with a view to achieving earlier arterial 
patency. This has been an attractive concept throughout the world, 










 Primary Percutaneous Coronary Inter-
vention (PCI) is the superior strategy for treating acute ST-
elevation myocardial infarction (STEMI) as an initial 
strategy within the fi rst 6 hours from symptom onset. 
Facilitation of PCI by the use of pre-treatment, prior to 
planned PCI, with thrombolytic drugs or glycoprotein (GP) 
IIb/IIIa inhibitors has held theoretical promise for earlier 
infarct related arterial patency, but has failed to deliver on 
such promise.
Thrombolysis as an initial strategy is inevitable in a large 
number of STEMI patients due to limited access to primary 
PCI. This strategy has limited success, and when it fails, 
rescue PCI has benefi t and is recommended.
Mechanical methods such as thrombectomy and distal 
protection, while having an intuitively plausible mechanism 
for benefi t, have also failed to meet expectations and have 






INTRODUCTION                                                                
Acute ST-elevation myocardial infarction (STEMI) is most often caused 
by thrombotic occlusion at the site of plaque rupture in a coronary 
artery.(1,2) The initial therapeutic goal is to achieve an open artery. 
Whatever method is used for reperfusion, this needs to be achieved in 
the shortest possible time in order to minimize the ischemic time: the 
greatest benefi t is accrued if reperfusion can be achieved within the 
fi rst 3 hours.(3) For many years research has focused on establishing 
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and results of randomized trials were eagerly awaited. The patient 
would theoretically receive the benefi t of both therapies.
The AHA, ACC update on management guidelines for ST-elevation 
MI(7) points out that facilitated PCI should be differentiated from 
primary PCI without fi brinolytic therapy, from primary PCI with a 
GPIIb/IIIa inhibitor started at the time of PCI, from early or delayed PCI 
after successful fi brinolytic therapy, and from rescue PCI after 
unsuccessful fi brinolytic therapy.
Several early randomized, placebo-controlled trials demonstrated a 
40% to 60% reduction in a 30-day composite ischemic end point 
(death, myocardial reinfarction and urgent target vessel revascularization 
[TVR]) with abciximab in this setting. The benefi t was primarily driven 
by a reduction in the rates of reinfarction and urgent TVR. No individual 
trial observed a statistically signifi cant reduction in 30-day mortality. 
These trials gave momentum to the facilitated PCI concept and led to 
larger trials assessing both GPIIb/IIIa inhibitors and thrombolytics in 
facilitated PCI.(8,9,10,11)
Indeed, facilitated PCI does achieve better patency rates and better 
TIMI 3 fl ow rates than does primary PCI, but this attractive strategy has 
ultimately failed to deliver on its theoretical promise. Keely et al. 
published a meta-analysis of 17 randomized trials comparing facilitated 
and primary angioplasty in 4 504 patients,(12) including the large 1 667 
patient ASSENT-4 trial.(13) The pharmacological agent was thrombolytic 
therapy alone in six trials, platelet glycoprotein IIb/IIIa (GPIIb/IIIa) 
antagonists alone in nine trials, and the combination of reduced dose 
thrombolysis (usually 50%) and GPIIb/IIIa antagonists in two trials. 
Facilitated PCI resulted in an increase in mortality, recurrent ischemia, 
major bleeding and stroke. Thrombolytic therapy was identifi ed as the 
culprit for adverse outcomes (either without or with GPIIb/IIIa 
antagonists). GPIIb/IIIa antagonists alone did not worsen outcomes but 
were not benefi cial. The ASSENT-4 PCI trial(14) was terminated 
prematurely because of a higher in-hospital mortality rate in the 
facilitated PCI group (6% vs. 3%; p=0.01).  
Possible explanations for these fi ndings are examined in an editorial 
accompanying the publication of the ASSENT-4 trial by Stone and 
Gersh.(15) Door-to-balloon times in experienced centres are now 
similar to the time it takes for a lytic to be administered and for the 
additional 60 minutes required for its effect. The lytic may therefore not 
be achieving its theoretical goal in advance of mechanical reperfusion. 
Also, the addition of lytic increases bleeding, which is in and of itself 
associated with mortality.(16) Increased myocardial haemorrhage can 
offset the myocardial salvage from reperfusion and can promote 
rupture. Finally, thrombolytic induced platelet activation may be 
responsible for increased reinfarction and emergency repeat 
revascularization. 
It would appear that facilitated PCI has all but had the door closed 
upon it. In the AHA, ACC update on management guidelines for 
ST-elevation MI,(7) facilitated PCI remains a possible option in a patient 
at a low risk of bleeding, with a high-risk infarct, and an anticipated very 
long time for transportation to a PCI centre. The ASSENT-4 trial, 
however, failed to suggest that such patients may benefi t from a 
facilitated approach.
Dr Steve Ellis presented the results of the FINESSE Trial at the 
European Society of Cardiology Congress in Vienna, Austria in 2007. 
The Trial randomized 2 452 patients to facilitated PCI with either up-
front abciximab plus half dose reteplase or up-front abciximab alone 
followed by PCI versus primary PCI alone. The study was terminated 
prematurely due to diffi culty with enrolment. There were no differences 
between groups in the primary endpoint of death or complications of 
MI (heart failure, arrhythmias or cardiogenic shock), and there was an 
increased incidence of bleeding in both facilitated groups. Thus 
thrombolytics cannot be recommended as pre-treatment for patients 
with STEMI in whom primary PCI is the planned treatment.
A meta-analysis of placebo-controlled abciximab trials for ST-segment 
elevation myocardial infarction (STEMI) did demonstrate a moderate 
reduction in mortality at 30 days (2.4% vs. 3.4%, p = 0.047) and at 6 to 
12 months (4.4% vs. 6.2%, p = 0.01) among those receiving abciximab 
during primary angioplasty. In a subsequent analysis of this combined 
dataset, the mortality benefi t was shown to be proportional to the 
baseline risk; the higher the risk, the higher the benefi t from 
abciximab.(17)
The data for GPIIb/IIIa antagonists is confl icting and there is not enough 
evidence to suggest routine pre-treatment with GPIIb/IIIa antagonists, 
but in higher risk patients, particularly in diabetics, and when there is 
visible thrombus, GPIIb/IIIa antagonists can be considered at the time 
of PCI. As mentioned earlier, this is not the same as facilitated PCI 
(i.e. pre-treatment) where they appear not to be benefi cial. 
How should community hospitals treat STEMI patients? Transfer of 
patients to an interventional hospital, in favour of thrombolysis, is 
advantageous if the time from arrival at the fi rst hospital to balloon 
dilatation at the destination hospital is under 2 hours.(18,19) Therefore, 
most patients presenting inside the 3-hour window, to a community 
hospital without PCI facilities, should still receive thrombolytic therapy. 
We await the outcomes of trials investigating the effects of withholding 
thrombolytic therapy when transfer times to an interventional facility 
are longer.
RESCUE PCI                                                                       
Thrombolysis is not universally successful. The rate of successful 
reperfusion (based on angiography at 90 minutes post-thrombolysis) 
is no better than 50%. The 2004 AHA, ACC STEMI Guidelines 
recommend urgent coronary angiography with intent to perform PCI, 
regardless of the time since initiation of fi brinolytic therapy, in certain 
patients: cardiogenic shock, severe congestive heart failure / pulmonary 
oedema or haemodynamically compromising ventricular arrhythmias.(20) 
These cases do not fall into the category of rescue PCI. Rescue PCI 
represents a strategy of PCI in patients who do not have the above 
clinical instability, but in whom there is the clinical suspicion of failed 
thrombolysis. Failure of resolution of chest pain is not a reliable gauge 
of reperfusion. Clinical assessment of reperfusion is best based on the 
degree of ST-segment resolution on the 12-lead ECG. If there is less 
than 50% ST-segment resolution in the lead showing the greatest 
degree of ST-segment elevation at presentation, fi brinolytic therapy has 
likely failed to produce reperfusion.(21)
The treatment for failed thrombolysis has included conservative 
management, repeat dose thrombolysis, and rescue PCI. The treatment 
of choice has been uncertain. Two recently published trials dealing with 
this subject are the REACT trial and the MERLIN trial.
REACT demonstrated that rescue PCI is associated with an improve-
ment in the combined end point of death, reinfarction, stroke, or severe 
heart failure, when compared with repeat fi brinolysis or conservative 
management.(22) The end point was driven mainly by a difference in 
reinfarction: there was no difference in mortality. MERLIN also did not 
demonstrate a difference in mortality when rescue PCI was compared 
with conservative therapy, but rescue PCI did reduce recurrent 
ischemia.(23) In both trials, bleeding, a predictor of adverse outcome, was 
increased.(22,23)
In order to obtain better guidance in treating this diffi cult problem of 
failed thrombolysis, Wijeysundera and colleagues have published a 
meta-analysis of 8 randomized trials, enrolling 1 177 patients, including 
REACT and MERLIN.(21) Six trials randomized 908 patients to rescue 
PCI vs. conservative therapy and 3 trials randomized 410 patients to 
repeat fi brinolysis or conservative therapy.
Rescue PCI was not associated with a signifi cant improvement in 
mortality compared with conservative therapy. Heart failure and 
reinfarction were, however, signifi cantly reduced with rescue PCI. The 
composite of death, heart failure and reinfarction was signifi cantly 
reduced by rescue PCI (p<0.001, number needed to treat = 9). Stroke 
was signifi cantly higher with rescue PCI (3.4% vs. 0.7%). Interestingly, 
most strokes were thrombo-embolic and not haemorrhagic, and 
numbers were small. There was no difference in major bleeding but 
minor bleeding was considerably higher with rescue PCI (16.6% vs. 
3.6%). The increased bleeding suggests that adjustments in antithrombotic 
medication dosing are required in order to improve safety.
The strategy of repeat fi brinolytic therapy for failed thrombolysis did 
not achieve a reduction in mortality or reinfarction. There was an 
increase in minor, but not major, bleeding. Stroke data was inadequate.
Another meta-analysis by Collet(24) evaluated 5 trials (920 patients). The 
odds ratios for death or reinfarction with rescue angioplasty versus 
conservative approach within the fi rst 30 days was 0.60 in favour of 
rescue PCI, p = 0.012.
These data support the use of rescue PCI, over conservative treatment, 
for failed fi brinolysis in STEMI. In contrast, repeat fi brinolysis cannot be 
recommended based on the available evidence.
The updated AHA, ACC STEMI guidelines make the point that low 
risk patients may be treated conservatively. Patients with symptom 
resolution and improving ST-segment elevation (but with less than 50% 
resolution), or inferior MI localized to 3 ECG leads, probably should 
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not be referred for angiography. The guidelines also highlight that the 
fi ndings at angiography are important: it is doubtful that PCI of a branch 
artery (diagonal or obtuse marginal branch) will change the prognosis 
in the absence of high-risk clinical criteria.
SYSTEMATIC EARLY PCI                                                 
In the Collet meta-analysis, six randomized trials were identifi ed for the 
comparison of systematic, early catheterization, versus delayed and/or 
ischemia-guided catheterization after fi brinolysis (1 508 patients). 
Patients underwent systematic PCI within 24 hours (mostly <6h) after 
thrombolysis. The overall analysis showed a non-signifi cant trend toward 
a reduction of death or myocardial infarction in the systematic early PCI 
group, without excess bleeding.(24) While systematic early PCI is a 
recommendation in the ESC guidelines,(25) there is little data upon 
which to make recommendations for adoption of such a strategy, 
but the meta-analysis indicates that early PCI after fi brinolysis is 
probably safe.
Mechanical methods to facilitate procedural success in 
STEMI PCI
A successful PCI procedure in the epicardial infarct-related artery is not 
equivalent to the restoration of myocardial perfusion at the cardiac 
microcirculation level. Distal embolization, slow-fl ow and no-fl ow 
phenomena occur in 30% of patients.(16) Following primary PCI, 
reperfusion of the microcirculation is assessed by the myocardial blush 
grade (MBG). A normal MBG 3 is seen in only one-third of patients, 
with two-thirds having impaired myocardial reperfusion (MBG 0-226). 
Patients with impaired microvascular reperfusion have increased early 
and late mortality and heart failure.(27) Distal embolization is an 
important player in failed microvascular reperfusion, while other 
mechanisms include vasospasm and edema of the surrounding 
myocardium.(28) Embolic material can include thrombus, plaque 
fragments, lipids, platelet clumps and neutrophils. 
Thrombectomy and distal protection are attractive modalities as 
adjuncts to primary PCI because of their theoretical ability to minimize 
distal embolisation.
Distal protection devices
Distal protection devices have proven to be of value in reducing distal 
embolization in saphenous vein graft PCI.(29,30) Distal protection showed 
early promise, but the EMERALD(31) trial did not demonstrate a benefi t 
for balloon distal protection in terms of ST-segment resolution or 
infarct size at 30 days. The PROMISE(32) trial, using a fi lter device, was 
also negative. In the PREMIAR(33) trial, the use of another fi lter-based 
distal protection device showed no advantage in improvement of 
myocardial reperfusion. Thus far a total of six trials with embolic-
protection devices have shown no benefi t of distal protection in the 
management of acute PCI for ST-elevation MI.
An area of possible further research for embolic protection remains 
the concept of proximal, or fl ow reversal protection, in which protection 
can be established before crossing the lesion with a guide wire.
Thrombectomy
A number of thrombectomy devices have been studied. The principles 
involved in device design varies from rheolytic thrombectomy (AngioJet 
- Possis Medical, Minneapolis, MN, USA), to a number of easy to use, 
cheaper aspiration devices. Early small studies showed improved ST-
segmentation resolution in STEMI patients with a large thrombus 
burden treated with thrombectomy during primary PCI. However, the 
AIMI trial of AngioJet thrombectomy, in all-comers with AMI, did not 
show benefi t for thrombectomy over conventional therapy.(34) Visible 
thrombus was not required for inclusion and critics of this trial cite the 
low thrombus burden as a major limitation. The ongoing JETSTENT 
trial, using the AngioJet device, will hopefully help to answer whether 
thrombectomy is helpful in patients with a large clot burden.
Of 10 trials evaluating thrombectomy devices, eight, mostly smaller 
studies, have shown some improvement in myocardial perfusion, while 
two bigger trials have shown no benefi t. One trial demonstrated 
possible harm from thrombectomy with an increase in infarct size 
compared to controls.(30) Interestingly, GPIIb/IIIa inhibitors have not 
been shown to impact on these outcomes.(36,37) A recent trial of the 
cheaper strategy of thrombus aspiration has shown potential benefi t of 
simple aspiration,(38) but this will require confi rmation in a larger trial.
The following can be deduced from the data currently available: 
thrombectomy cannot be recommended for routine use in primary 
PCI, as most patients do not benefi t. The role for thrombectomy, most 
likely, lies in the patient with a large thrombus burden. In such cases PCI 
is technically very diffi cult and thrombectomy makes the procedure less 
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complicated to perform. The Jetstent trial will, hopefully, shed light 
on the role of thrombus extraction in this specifi c subgroup of 
AMI patients.
CONCLUSIONS                                                                  
It is now well established that primary PCI is a superior strategy for 
treating acute STEMI as an initial strategy within the fi rst 6 hours from 
symptom onset. Facilitated PCI is a strategy that is of no benefi t and 
neither GPIIbIIIa inhibitors nor thrombolytics are recommended as 
upfront treatment before planned PCI.
Primary PCI is not widely applicable in South Africa and therefore most 
patients with ST-elevation MI will receive thrombolysis. When 
thrombolysis fails, as indicated by failure of ST-segment elevation to 
resolve within 90 minutes, rescue PCI is recommended.
Early PCI within 24 hours of lytic therapy is not of proven benefi t but 
appears to be safe.
In patients with ST-elevation MI who undergo  primary PCI, 
thrombectomy may be a useful adjunct in the presence of a large 
thrombus burden but is of no benefi t in other situations. Distal 
protection does not seem to have a role in acute myocardial 
infarction.
An important message from the facilitated PCI, thrombectomy and 
distal protection trials is that many therapeutic concepts that appear 
intuitively logical don’t stand up to the rigorous scrutiny of randomized 
trials.
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